NCT05443126 2026-02-03
A Study of EP0031 in Patients With Advanced RET-altered Malignancies
Ellipses Pharma
Phase 1/2 Recruiting
Clinical Trials
4 trialsNCT06130254 2025-10-14
Phase Ib Trial of the KRAS G12C Inhibitor Adagrasib (MRTX849) in Combination With the PARP Inhibitor Olaparib in Patients With KRAS G12C Mutated Advanced Solid Tumors, With a Focus on Gynecological, Breast, Pancreatic and KEAP1 Mutated Non-small Cell Lung Cancers
M.D. Anderson Cancer Center
Phase 1 Recruiting
NCT05417321 2025-01-03
A Study Evaluating the Safety and Efficacy of HB0036 in Subjects With Advanced Solid Tumors
Shanghai Huaota Biopharmaceutical Co., Ltd.
Phase 1/2 Recruiting
NCT05772455 2024-10-28
A Study of XZB-0004 in Patients With Solid Tumors
Xuanzhu Biopharmaceutical Co., Ltd.
Phase 1 Recruiting